Hypereosinophilic syndrome

This Phase 3 trial tests the drug benralizumab (Fasenra) in children aged 6 to 17 with two rare eosinophilic diseases: EGPA and HES. The study aims to see if the drug is safe, how it works in the body, and whether it can help control the disease. Fourteen children will receive in…

This study tests a drug called depemokimab in adults with hypereosinophilic syndrome (HES), a rare condition where too many eosinophils (a type of white blood cell) cause organ damage. The trial includes 123 people whose HES is not well controlled despite standard therapy. Partic…

This study tests whether adding dupilumab to standard treatment can help people with hypereosinophilic syndrome (HES) who still have symptoms despite current biologic therapy. About 30 adults will receive dupilumab injections for up to 48 weeks while continuing their usual medica…

This study gives ongoing access to benralizumab (Fasenra) for people with asthma, eosinophilic granulomatosis with polyangiitis (EGPA), or hypereosinophilic syndrome (HES) who completed a prior benralizumab trial and still benefit from the drug. About 230 participants will receiv…

This study follows about 50 members of a family with a rare inherited condition called familial hypereosinophilia, where high levels of a type of white blood cell can damage the heart and nerves. Researchers will track participants over many years with yearly checkups, blood test…

This study aims to understand how and why eosinophils (a type of white blood cell) become active in conditions like allergies, asthma, and parasitic infections. Researchers will observe up to 800 people aged 1 to 100 with high eosinophil levels. No experimental treatments are giv…

This study is collecting information from 600 people with chronically high levels of eosinophils (a type of white blood cell) or related organ damage. Researchers want to describe the different symptoms, disease patterns, and genetic factors involved. The goal is to better unders…

This study collects medical data from 60 adults diagnosed with either EGPA or HES, two rare conditions that cause high levels of a type of white blood cell. Researchers will use artificial intelligence to find patterns that help doctors tell the diseases apart and predict how pat…